Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide versus dulaglutide in Japanese participants (phase 3)
jRCT2080225215Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised trial of tirzepatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Started Jun 2020; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080225215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225215.